Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-09
2011-08-09
Landau, Sharmila G. (Department: 1611)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S256000
Reexamination Certificate
active
07994184
ABSTRACT:
This invention provides a novel screening system for identifying p53 mimetics/agonists. Also provided are small organic molecules that act as effective p53 mimetics/agonists.
REFERENCES:
patent: 4698176 (1987-10-01), Gray et al.
patent: 4699789 (1987-10-01), Schultz
patent: 4844911 (1989-07-01), Kakimoto et al.
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5519134 (1996-05-01), Acevedo et al.
patent: 5525735 (1996-06-01), Gallop et al.
patent: 5539083 (1996-07-01), Cook et al.
patent: 5549974 (1996-08-01), Holmes
patent: 5569588 (1996-10-01), Ashby et al.
patent: 5593853 (1997-01-01), Chen et al.
patent: 5744310 (1998-04-01), Reed
patent: 5837838 (1998-11-01), Reed et al.
patent: 5856362 (1999-01-01), Hudson
patent: 6228850 (2001-05-01), Jaggi et al.
patent: 6235714 (2001-05-01), Paul et al.
patent: 6274732 (2001-08-01), Cho et al.
patent: 6479466 (2002-11-01), Redfield et al.
patent: 6693194 (2004-02-01), Jau et al.
patent: 6 256113 (1994-09-01), None
patent: WO-91/19735 (1991-12-01), None
patent: WO-92/00091 (1992-01-01), None
patent: WO-93/20242 (1993-10-01), None
patent: WO 95/19367 (1995-07-01), None
patent: WO-97/00271 (1997-01-01), None
patent: WO-2006/023410 (2006-03-01), None
Baker et al. Journal of Medicinal Chemistry (1969), 12(1), 74-8.
Baker et al. Irreversible enzyme inhibitors. CXXXIV. Effect of ring substitution on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylphenylureido)phenoxymethyl]pyrimidine, Jan. 1969.
Choi et al. Identification of highly potent and selective inhibition ofToxoplasma gondiidihydrofolase reductase. Antimicrobial Agents and Chemotherapy. 1993;37(9): 1914-1923.
Baker et al. J. Med. Chem. 1968, 11, 495-500.
Xu et al. “Statistical cluster analysis of pharmaceutical solvents”, International Journal of Pharmaceutics, 2007, 229, 175-188.
Baum, R. (Jan. 18, 1993). “Solid-Phase Synthesis of Benzodiazepines,”C&EN, pp. 33-34.
Campbell, D.A. et al. (Feb. 11, 1994). “Phosphonate Ester Synthesis Using a Modified Mitsunobu Condensation,”J. Org. Chem.59(3):658-660.
Chen, C. et al. (Mar. 23, 1994). “‘Analogous’ Organic Synthesis of Small-Compound Libraries: Validation of Combinatorial Chemistry in Small-Molecule Synthesis,”J. Am. Chem. Soc.116(6):2661-2662.
Cho, C. Y. et al. (Sep. 3, 1993). “An Unnatural Biopolymer,”Science261(5126):1303-1305.
Dewitt, S. H. et al. (Aug. 1993). “‘Diversomers’: An Approach to Nonpeptide, Nonoligomeric Chemical Diversity,”Proc. Natl. Acad. Sci. USA90:6909-6913.
Furka, Á. (Jun. 1991). “General Method for Rapid Synthesis of Multicomponent Peptide Mixtures,”Int. J. Pept. Prot. Res.37(6):487-493.
Gallop, M.A. et al. (Apr. 29, 1994). “Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries,”J. Med. Chem.37(9):1233-1251.
Gordon, E.M. et al. (May 13, 1994). “Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions,”J. Med. Chem.37(10):1385-1401.
Hagihara, M. et al. (Jul. 29, 1992). “Vinylogous Polypeptides: An Alternative Peptide Backbone,”J. Am. Chem. Soc.114(16):6568-6470.
Hirschmann, R. et al. (Nov. 4, 1992). “Nonpeptidal Peptidomimetics with a β-D-Glucose Scaffolding. A Partial Somatostatin Agonist Bearing a Close Structural Relationship to a Potent, Selective Substance P Antagonist,”J. Amer. Chem. Soc.114(23):9217-9218.
Houghton, R.A. et al. (Nov. 7, 1991). “Generation and Use of Synthetic Peptide Combinatorial Libraries for Basic Research and Drug Discovery,”Nature354(6348):84-87.
Krajewski, S. et al. (Oct. 1, 1995). “Reduced Expression of Proapoptotic GeneBAXis Associated with Poor Response Rates to Combination Chemotherapy and Shorter Survival in Women with Metastatic Breast Adenocarcinoma,”Cancer Res.55:4471-4478.
Lai, H. et al. (Jan. 1, 2004). “Spectrum of p53 Tumor Suppressor Gene Mutations and Breast Cancer Survival,”Breast Cancer Res. Treat.83(1):57-66.
Liang, R. et al. (Nov. 29, 1996). “Parallel Synthesis and Screening of a Solid Phase Carbohydrate Library,”Science274:1520-1522.
Miyashita, T. et al. (Jan. 27, 1995). “Tumor Suppressor p53 is a Direct Transcriptional Activator of the HumanbaxGene,”Cell80:293-299.
Reed, J.C. (1996). “Balancing Cell Life and Death: Bax, Apoptosis, and Breast Cancer,”J. Clin. Invest.97(11):2403-2404.
Vaughan, T.J. et al. (Mar. 1996). “Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library,”Nat. Biotechnol.14(3):309-314.
International Search Report mailed on Jun. 5, 2008, for PCT/US05/28857, filed on Aug. 12, 2005, four pages.
Written Opinion mailed on Jun. 5, 2008, for PCT/US05/28857, filed on Aug. 12, 2005, four pages.
Bargou, R.C. et al. (Jun. 1996). “Overexpression of the Death-promoting Gene bax-α Which is Downregulated in Breast Cancer Restores Sensitivity to Different Apoptotic Stimuli and Reduces Tumor Growth in SCID Mice,”J. Clin. Invest.97(11):2651-2659.
Baker, B.R. et al. (Jan. 1, 1970). “Irreversible Enzyme Inhibitors. CLXVI. Active-Site-Directed Irreversible Inhibitors of Dihydrofolic Reductase derived from 2,4-Diamino-5-(3,4-Dichlorophenyl) Pyrimidine with 6 Substitutents and Some Factors in Their Cell Wall Transport,”J. Med. Chem.13(1):82-86.
Bykov, V. J. N. et al. (Sep. 1, 2003). “Small Molecules that Reactivate Mutant p53,”European Journal of Cancer39(13):1828-1834.
Choudhuri, T. et al. (Feb. 13, 2002). “Curcumin Induces Apoptosis in Human Breast Cancer Cells Through p53-Dependent Bax Induction,”FEBS Letters512(1-3):334-340.
Liontas, A. et al. (Mar. 1, 2004). “Curcumin and Resveratrol Induce Apoptosis and Nuclear Translocation and Activation of p53 in Human Neuroblastoma,”Anticancer Research, 24(2B):987-998.
Lin, H.-Y. et al. (Aug. 1, 2002). “Resveratrol Induced Serine Phosphorylation of p53 Causes Apoptosis in a Mutant p53 Prostate Cancer Cell Line,”Journal of Urology168(2):748-755.
Watabe, M. et al. (Feb. 13, 2004). “Caffeic Acid Phenethyl Ester Induces Apoptosis by Inhibition of NFkappaB and Activation of Fas in Human Breast Cancer MCF-7 Cells,”J. Biol. Chem.279(7):6017-6026.
Supplementary European Search Report mailed Oct. 13, 2009, for European Patent Application No. 05786671.7 filed on Aug. 12, 2005 and published under European Publication No. 1 786 430 on May 23, 2007, 9 pages.
European Search Opinion mailed Oct. 13, 2009, for European Patent Application No. 05786671.7 filed on Aug. 12, 2005 and published under European Publication No. 1 786 430 on May 23, 2007, 8 pages.
Baker, B. R. et al. (Jan. 1969). “Irreversible Enzyme Inhibitors. CXXXV. Effect of Ring Substitution on the Selective Irreversible Inhibition of Dihydrofolic Reductase from L1210 Mouse Leukemia and Liver by 2,4-Diamino-5-(3,4-dichlorophenyl)-6-[p-(p-fluorosulfonylphenylureido)phenoxymethyl]pyrimidine,”J. Med. Chem.12(1):79-81.
Business and Professions Code (California) (2010). Section 4127-4127.8, located at http://www.leginfo.ca.gov/cgi-bin/displaycode?section=bpc&group=04001-05000&file=4127-4127.8, last visited Dec. 6, 2010, 3 pages.
California Code of Regulations (2010). Title 16 entitled “Professional and Vocational Regulations”, Division 17 “California State Board of Pharmacy,” vol. 21, published by West®, pp. i-iii, pp. 334.5-334.6(c).
Dvorkin, V. M. (May 1985). “Preparation of Liposomes, Using Phase Reversal Technique Excluding Ultrasonic Treatment,” original Russian article located in Biokhimiya (publication of the Academy of Sciences
Bredesen Dale E.
Niazi Kayvan
Rabizadeh Shahrooz
Buck Institute
Klinkel Kortney L
Landau Sharmila G.
Morrison & Foerster / LLP
LandOfFree
Small molecules that replace or agonize p53 function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Small molecules that replace or agonize p53 function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Small molecules that replace or agonize p53 function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2701942